Life Sciences AI Governance
How to Choose the Best AI Governance Consulting Firm for a Pharmaceutical Company
Most firms pitching AI governance for pharma have never sat across from an FDA investigator or written a validation package that had to survive one. The right firm has.
The best AI governance consulting firm for a pharmaceutical company is not the largest generalist, it is one with direct 21 CFR Part 11 and GxP experience, working knowledge of the FDA's 2025 AI credibility framework, familiarity with GAMP 5's AI/ML validation appendix, and evidence of independent model validation work rather than marketing claims alone.
criteria
What Separates a Qualified AI Governance Firm From a Generalist
The best AI governance consulting firm for a pharmaceutical company is not the largest generalist, it is one with direct 21 CFR Part 11 and GxP experience, working knowledge of the FDA's 2025 AI credibility framework, familiarity with GAMP 5's AI/ML validation appendix, and evidence of independent model validation work rather than marketing claims alone.
GxP and 21 CFR Part 11 Fluency, Not Just AI Fluency
A firm that can explain a transformer architecture but has never assembled a 21 CFR Part 11 validation package will not know what an FDA investigator actually asks for during an inspection: audit trail integrity, electronic signature controls, and evidence that the system was validated for its intended use before it touched regulated data. AI expertise without that background produces a system that works technically and fails procedurally.
Part 11 governs electronic records and electronic signatures used to meet any predicate FDA requirement, and it does not carve out an exception for AI-generated or AI-assisted records. A model that drafts a batch record annotation, flags a deviation, or supports a regulatory submission is producing an electronic record under Part 11's scope the moment that output feeds a decision the FDA cares about.
Experience With the FDA's AI Credibility Framework
The FDA issued its first dedicated AI guidance, Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products, in January 2025, proposing a risk-based credibility assessment framework tied to a defined context of use. It covers AI models used in the nonclinical, clinical, post-marketing, and manufacturing phases of the product lifecycle, specifically where the model's output is meant to support a regulatory decision about safety, efficacy, or quality, and it deliberately excludes AI used only in early discovery or in operational tasks that do not touch patient safety or data reliability.
A firm worth hiring should be able to walk you through what 'context of use' means for your specific model, not recite the guidance's title. On January 14, 2026, the FDA and the European Medicines Agency jointly published Guiding Principles of Good AI Practice in Drug Development, a set of ten principles covering risk-based deployment, data governance, multidisciplinary review, and life cycle management across both agencies' expectations. A firm that only knows the U.S. side of this is already behind for any sponsor running trials in both jurisdictions.
GAMP 5 Appendix D11 and the AI/ML Validation Lifecycle
ISPE's GAMP 5 Second Edition added a new appendix, D11, specifically for AI and machine learning systems, covering intended-use definition, training data selection, performance metric selection, and continuous monitoring once a model is in production, the same lifecycle discipline GAMP 5 has long required for other GxP computerized systems, extended to account for models that keep learning after deployment. ISPE followed that in July 2025 with a standalone GAMP Guide on Artificial Intelligence, a full-length guide extending GAMP 5 principles specifically to AI-enabled systems across their entire lifecycle.
A firm citing GAMP 5 in a pitch deck without being able to describe what Appendix D11 actually changes about validating an adaptive model, versus a static one, has not done the reading. Ask them directly what continuous performance monitoring looks like for a model that updates on new data versus one that was locked at validation.
Independent Validation Capacity, Not Just Implementation
A firm that built or sold you the AI system cannot credibly validate it independently, the same conflict quality systems have guarded against for decades in traditional computerized system validation. The firm you hire to validate a clinical AI tool, review a vendor's model documentation, or prepare a Part 11 evidence package should be structurally separate from whoever built the tool, with the standing to flag a gap rather than defend a sale.
evidence
What the 2025-2026 Regulatory and Industry Record Shows
Pharma's AI governance landscape moved fast in a short window. The FDA's January 2025 draft guidance was the agency's first dedicated framework for AI in drug and biologic regulatory decisions. Less than a year later, on January 14, 2026, the FDA and EMA jointly released their Guiding Principles of Good AI Practice in Drug Development, signaling that transatlantic alignment, not a single-agency standard, is where this is heading. Neither document is a casual reference; sponsors preparing an AI-supported submission are expected to show their work against both.
On the standards side, ISPE's GAMP 5 Second Edition and its Appendix D11 gave the industry its first widely adopted, vendor-neutral framework specifically for validating AI and machine learning systems inside a GxP environment, rather than forcing AI into validation templates built for deterministic software.
The operational gap behind all of this is real and measured. A 2026 survey by analytics firm HexaData of more than 30 drug manufacturers found that 72% of respondents said their data was not ready for AI implementation, and only 8% of AI pilot projects reached full-scale deployment, most stalling on fragmented data systems and the absence of a formal data governance function. That gap is exactly where an AI governance firm's actual value shows up: not in building a model, but in making the surrounding data, documentation, and validation structure defensible enough for a model to be deployed and to survive an inspection afterward.
framework
The Evaluation Checklist Before You Hire a Pharma AI Governance Firm
Six questions separate a firm that can actually do this work from one that has repackaged a generic AI consulting deck for a life sciences audience.
1. Can they show a prior GxP or Part 11 validation deliverable, not just describe one?
Ask to see redacted evidence of a validation package, audit trail review, or Part 11 gap assessment they actually produced, not a template or a slide.
2. Can they explain your model's context of use under the FDA's credibility framework?
If they cannot map your specific AI use case to the framework's risk tiers within the conversation, they have not internalized it.
3. Do they know what changed in GAMP 5 Appendix D11 specifically?
A firm that cites GAMP 5 generically without being able to describe the AI/ML-specific lifecycle requirements in Appendix D11 is working from an old playbook.
4. Will they review data governance and readiness before touching the model?
Given how often AI stalls on data quality rather than model quality, a firm that jumps straight to model validation without assessing the data feeding it is skipping the step most likely to fail.
5. Are they structurally independent from the system they would be validating?
If the same firm built or sold the AI tool, they cannot also be your independent validator without the same conflict traditional CSV practice has always guarded against.
6. Can their documentation survive an inspector who was not in the room?
Ask for a sample of how they document a decision or a validation rationale. If it only makes sense with a live explanation, it will not hold up months later during an inspection.
differentiation
How Kriv AI Approaches Pharmaceutical AI Governance Engagements
Kriv AI's life sciences practice runs GxP and 21 CFR Part 11 validation, FDA AI-credibility-framework readiness reviews, GAMP 5 Appendix D11 gap assessments, and independent vendor model validation for pharmaceutical, biotech, and clinical research organizations. The practice is structurally separate from any AI vendor or system builder, so a validation finding is never softened by a sales relationship.
Engagements start with a data and model inventory, mapped against Part 11 scope and the FDA's context-of-use categories, before any validation work begins, directly because data readiness, not model sophistication, is where most pharma AI efforts stall. Regulated life sciences work is billed at a $200 per hour floor, with an $8,000 minimum engagement, and specialized model-validation or explainability advisory work at $400 to $700 per hour, consistent with the rest of Kriv AI's regulated-industry engagements.
See our dedicated pages on 21 CFR Part 11 AI validation consulting and GCP and GAMP 5 clinical AI validation consulting for the specific validation work each standard requires, or book a discovery call to walk through where your current AI governance program has gaps before your next inspection or submission.
Sources
Cited sources
- FDA Draft Guidance, Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products (January 2025)
- FDA and EMA, Guiding Principles of Good AI Practice in Drug Development, jointly released January 14, 2026
- ISPE, GAMP 5 Guide, Second Edition, including Appendix D11 on AI/ML systems
- eCFR, 21 CFR Part 11, Electronic Records; Electronic Signatures
- A 2026 survey by analytics firm HexaData of more than 30 drug manufacturers found 72% of respondents said their data was not ready for AI implementation, and only 8% of AI pilot projects reached full-scale deployment.
- Kriv AI regulated life sciences engagements are billed at a $200 per hour floor with an $8,000 minimum, and specialized model-validation advisory work at $400 to $700 per hour.
Straight answers
Frequently asked questions about How to Choose the Best AI Governance Consulting Firm for a Pharmaceutical Company
What is the best AI governance consulting firm for a pharmaceutical company?
There is no single universally-best firm, the right one depends on your specific AI use case, but the qualifying criteria are consistent: direct 21 CFR Part 11 and GxP validation experience, working knowledge of the FDA's January 2025 AI credibility framework and the January 2026 FDA-EMA Guiding Principles, familiarity with GAMP 5 Appendix D11, and structural independence from whoever built the AI system, so the validation is not compromised by a sales relationship.
What is the FDA's AI credibility assessment framework?
It is the risk-based framework the FDA proposed in its January 2025 draft guidance, Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products. It ties the depth of evidence required to establish an AI model's credibility to that model's defined context of use, covering models used in the nonclinical, clinical, post-marketing, and manufacturing phases of the product lifecycle.
What is GAMP 5 Appendix D11 and why does it matter for AI vendor selection?
Appendix D11 is the addition ISPE made to GAMP 5 Second Edition specifically for AI and machine learning systems, covering intended-use definition, training data selection, performance metrics, and continuous monitoring for models that keep learning after deployment. A consulting firm that cannot describe what it changes about validating an adaptive model, compared to a static one, has not actually worked with it.
Why can't the firm that built our AI system also validate it?
Independent validation requires the reviewer to have the standing to flag a gap rather than defend a system they have a financial or reputational stake in. This is the same conflict traditional computerized system validation has guarded against for decades, and it applies with the same force to AI systems, if anything more, given how much documentation and context-of-use justification an AI validation package requires.
How ready is the pharmaceutical industry for AI deployment right now?
Not very, by the industry's own measurement. A 2026 survey by analytics firm HexaData of more than 30 drug manufacturers found 72% of respondents said their data was not ready for AI implementation, and only 8% of AI pilot projects reached full-scale deployment. Most of that gap traces back to fragmented data systems and the absence of a formal data governance function, not to model quality.
What did the FDA and EMA's January 2026 Guiding Principles add to the FDA's own 2025 guidance?
The Guiding Principles of Good AI Practice in Drug Development, released jointly by the FDA and EMA on January 14, 2026, are ten high-level principles covering risk-based deployment, data governance, multidisciplinary expertise, and life cycle management across both agencies, signaling that a sponsor developing AI-supported evidence for both U.S. and EU submissions needs a governance approach that satisfies both frameworks, not just the FDA's.
Talk to the team that would do the work
Bring your requirements to a working session with the person who'll actually deliver.
Book a Discovery Call